141 related articles for article (PubMed ID: 25011025)
1. Optical coherence tomography-based ranibizumab monotherapy for retinal angiomatous proliferation in Korean patients.
Shin JY; Yu HG
Retina; 2014 Dec; 34(12):2359-66. PubMed ID: 25011025
[TBL] [Abstract][Full Text] [Related]
2. Long-term visual outcome and prognostic factors of Intravitreal anti-vascular endothelial growth factor treatment for retinal angiomatous proliferation.
Cho HJ; Lee TG; Han SY; Kim HS; Kim JH; Han JI; Lew YJ; Kim JW
Graefes Arch Clin Exp Ophthalmol; 2016 Jan; 254(1):23-30. PubMed ID: 25825231
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal anti-vascular endothelial growth factor for retinal angiomatous proliferation in treatment-naive eyes: long-term functional and anatomical results using a modified PrONTO-style regimen.
Gharbiya M; Parisi F; Cruciani F; Bozzoni-Pantaleoni F; Pranno F; Abdolrahimzadeh S
Retina; 2014 Feb; 34(2):298-305. PubMed ID: 23807188
[TBL] [Abstract][Full Text] [Related]
4. Combination treatment of photodynamic therapy with verteporfin and intravitreal ranibizumab in patients with retinal angiomatous proliferation.
Seidel G; Werner C; Weger M; Steinbrugger I; Haas A
Acta Ophthalmol; 2013 Sep; 91(6):e482-5. PubMed ID: 23786546
[TBL] [Abstract][Full Text] [Related]
5. Ranibizumab in retinal angiomatous proliferation (RAP): influence of RAP stage on visual outcome.
Reche-Frutos J; Calvo-Gonzalez C; Pérez-Trigo S; Fernandez-Perez C; Donate-Lopez J; Garcia-Feijoo J
Eur J Ophthalmol; 2011; 21(6):783-8. PubMed ID: 21484755
[TBL] [Abstract][Full Text] [Related]
6. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration.
Ying GS; Huang J; Maguire MG; Jaffe GJ; Grunwald JE; Toth C; Daniel E; Klein M; Pieramici D; Wells J; Martin DF;
Ophthalmology; 2013 Jan; 120(1):122-9. PubMed ID: 23047002
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal ranibizumab treatment of retinal angiomatous proliferation.
Kramann CA; Schöpfer K; Lorenz K; Zwiener I; Stoffelns BM; Pfeiffer N
Acta Ophthalmol; 2012 Aug; 90(5):487-91. PubMed ID: 20584002
[TBL] [Abstract][Full Text] [Related]
8. One year results of intravitreal ranibizumab monotherapy for retinal angiomatous proliferation: a comparative analysis based on disease stages.
Park YG; Roh YJ
BMC Ophthalmol; 2015 Dec; 15():182. PubMed ID: 26691185
[TBL] [Abstract][Full Text] [Related]
9. Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).
Daniel E; Shaffer J; Ying GS; Grunwald JE; Martin DF; Jaffe GJ; Maguire MG;
Ophthalmology; 2016 Mar; 123(3):609-16. PubMed ID: 26681392
[TBL] [Abstract][Full Text] [Related]
10. Subfoveal choroidal thickness changes after intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation.
Maruko I; Iida T; Oyamada H; Sugano Y; Saito M; Sekiryu T
Retina; 2015 Apr; 35(4):648-54. PubMed ID: 25627088
[TBL] [Abstract][Full Text] [Related]
11. Two-year results of combined intravitreal anti-VEGF agents and photodynamic therapy for retinal angiomatous proliferation.
Saito M; Iida T; Kano M
Jpn J Ophthalmol; 2013 Mar; 57(2):211-20. PubMed ID: 23208024
[TBL] [Abstract][Full Text] [Related]
12. Long-term results of intravitreal ranibizumab for the treatment of retinal angiomatous proliferation and utility of an advanced RPE analysis performed using spectral-domain optical coherence tomography.
Inoue M; Arakawa A; Yamane S; Kadonosono K
Br J Ophthalmol; 2014 Jul; 98(7):956-60. PubMed ID: 24599418
[TBL] [Abstract][Full Text] [Related]
13. Two-year results of combined intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation.
Saito M; Iida T; Kano M; Itagaki K
Jpn J Ophthalmol; 2016 Jan; 60(1):42-50. PubMed ID: 26498642
[TBL] [Abstract][Full Text] [Related]
14. Ranibizumab for retinal angiomatous proliferation in neovascular age-related macular degeneration.
Lai TY; Chan WM; Liu DT; Lam DS
Graefes Arch Clin Exp Ophthalmol; 2007 Dec; 245(12):1877-80. PubMed ID: 17901972
[TBL] [Abstract][Full Text] [Related]
15. Genetic factors associated with response to intravitreal ranibizumab in Korean patients with neovascular age-related macular degeneration.
Park UC; Shin JY; Kim SJ; Shin ES; Lee JE; McCarthy LC; Newcombe PJ; Xu CF; Chung H; Yu HG
Retina; 2014 Feb; 34(2):288-97. PubMed ID: 23842101
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab versus ranibizumab for the treatment of retinal angiomatous proliferation.
Parodi MB; Iacono P; Menchini F; Sheth S; Polini G; Pittino R; Bandello F
Acta Ophthalmol; 2013 May; 91(3):267-73. PubMed ID: 21951313
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP).
Konstantinidis L; Mameletzi E; Mantel I; Pournaras JA; Zografos L; Ambresin A
Graefes Arch Clin Exp Ophthalmol; 2009 Sep; 247(9):1165-71. PubMed ID: 19404661
[TBL] [Abstract][Full Text] [Related]
18. FUSION regimen: ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and relatively good baseline visual acuity.
Monés J; Biarnés M; Trindade F; Casaroli-Marano R
Graefes Arch Clin Exp Ophthalmol; 2012 Dec; 250(12):1737-44. PubMed ID: 22527314
[TBL] [Abstract][Full Text] [Related]
19. Visual and morphological outcomes of bevacizumab (Avastin®) versus ranibizumab (Lucentis®) treatment for retinal angiomatous proliferation.
Hufendiek K; Hufendiek K; Panagakis G; Helbig H; Gamulescu MA
Int Ophthalmol; 2012 Jun; 32(3):259-68. PubMed ID: 22527448
[TBL] [Abstract][Full Text] [Related]
20. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab.
Cho HJ; Kim CG; Yoo SJ; Cho SW; Lee DW; Kim JW; Lee JH
Am J Ophthalmol; 2013 Jan; 155(1):118-126.e1. PubMed ID: 23022163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
